Sage Therapeutics Stock Forecast, Price & News

+0.35 (+0.47 %)
(As of 04/22/2021 12:00 AM ET)
Today's Range
Now: $74.72
50-Day Range
MA: $75.85
52-Week Range
Now: $74.72
Volume410,681 shs
Average Volume494,138 shs
Market Capitalization$4.36 billion
P/E RatioN/A
Dividend YieldN/A
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Sage Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SAGE
Year FoundedN/A



Sales & Book Value

Annual Sales$6.87 million
Book Value$18.23 per share


Net Income$-680,240,000.00
Net Margins-7,706.84%


Market Cap$4.36 billion
Next Earnings Date5/4/2021 (Confirmed)


Is SAGE Stock A Buy or Sell?
April 14, 2021 |
Sage Therapeutics (NASDAQ:SAGE) Shares Up 8%
April 14, 2021 |
Sage Therapeutics (NASDAQ:SAGE) Stock Price Down 5.6%
April 13, 2021 |
Sage Therapeutics' (SAGE) Hold Rating Reiterated at Mizuho
April 12, 2021 |
Sage Therapeutics (NASDAQ:SAGE) Sees Large Volume Increase
April 6, 2021 |
See More Headlines


Overall MarketRank

1.40 out of 5 stars

Medical Sector

660th out of 2,024 stocks

Pharmaceutical Preparations Industry

318th out of 771 stocks

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
+0.35 (+0.47 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sage Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

Is Sage Therapeutics a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sage Therapeutics stock.
View analyst ratings for Sage Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Sage Therapeutics?

Wall Street analysts have given Sage Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sage Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sage Therapeutics' next earnings date?

Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Sage Therapeutics

How can I listen to Sage Therapeutics' earnings call?

Sage Therapeutics will be holding an earnings conference call on Tuesday, May 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its quarterly earnings results on Wednesday, February, 24th. The biopharmaceutical company reported $18.19 earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.17) by $20.36. The biopharmaceutical company had revenue of $1.69 million for the quarter, compared to the consensus estimate of $1.86 million. Sage Therapeutics had a negative net margin of 7,706.84% and a negative trailing twelve-month return on equity of 63.81%.
View Sage Therapeutics' earnings history

How has Sage Therapeutics' stock been impacted by Coronavirus?

Sage Therapeutics' stock was trading at $42.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SAGE stock has increased by 76.6% and is now trading at $74.72.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SAGE?

16 analysts have issued 12-month target prices for Sage Therapeutics' stock. Their forecasts range from $35.00 to $135.00. On average, they anticipate Sage Therapeutics' share price to reach $86.69 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price.
View analysts' price targets for Sage Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sage Therapeutics' key executives?

Sage Therapeutics' management team includes the following people:
  • Ms. Kimi E. Iguchi, CFO & Treasurer (Age 59, Pay $536.37k)
  • Mr. Michael Cloonan, Chief Operating Officer (Age 49, Pay $582.75k)
  • Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 59, Pay $564.84k)
  • Dr. Jeffrey M. Jonas, Chief Innovation Officer, Chair of the Science & Technology Forum and Director (Age 68, Pay $983.77k)
  • Dr. Stephen J. Kanes, Chief Medical Officer (Age 56, Pay $580.67k)
  • Mr. Barry E. Greene, Pres, CEO & Director (Age 58)
  • Dr. Heinrich Schlieker Ph.D., Sr. VP of Technical Operations
  • Dr. Albert J. Robichaud, Chief Scientific Officer (Age 60)
  • Mr. Matthew Calistri, VP of Investor Relations
  • Ms. Erin E. Lanciani, Sr. VP of People & Organizational Strategy (Age 52)

Who are some of Sage Therapeutics' key competitors?

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Tributary Capital Management LLC (0.03%), Polianta Ltd (0.03%), State of Alaska Department of Revenue (0.01%), HighPoint Advisor Group LLC (0.01%), Pacer Advisors Inc. (0.00%) and Private Capital Group LLC (0.00%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas and Michael Cloonan.
View institutional ownership trends for Sage Therapeutics

Which institutional investors are selling Sage Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Sage Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Sage Therapeutics stock?

SAGE stock was purchased by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Polianta Ltd, State of Alaska Department of Revenue, Private Capital Group LLC, and HighPoint Advisor Group LLC. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas.
View insider buying and selling activity for Sage Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sage Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $74.72.

How much money does Sage Therapeutics make?

Sage Therapeutics has a market capitalization of $4.36 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis.

How many employees does Sage Therapeutics have?

Sage Therapeutics employs 298 workers across the globe.

What is Sage Therapeutics' official website?

The official website for Sage Therapeutics is

Where are Sage Therapeutics' headquarters?

Sage Therapeutics is headquartered at 215 FIRST STREET, CAMBRIDGE MA, 02142.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]

This page was last updated on 4/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.